Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of 18F-DCFPyL-PSMA PET in Patients Receiving 177Lu-Vipivotide Tetraxetan Therapy for Metastatic Castrate-resistant Prostate Cancer

NCT06099093 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT06099093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06099093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of 18F-DCFPyL-PSMA PET in Patients Receiving 177Lu-Vipivotide Tetraxetan Therapy for Metastatic Castrate-resistant Prostate Cancer
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
April 1, 2024
Completion date
December 1, 2026
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer, metastatic castration-resistant prostate carcinoma, prostate cancer